Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2022-02-08
2025-12-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Simulated Night Shift Work
Two inpatient stays, each involving a baseline night, followed by a 3-hour afternoon nap opportunity, and then three 12-hour night shifts, with 8-hour daytime sleep opportunity in between.
Simulated short term night shift work schedule
Participant sleep schedules (in the experimental arm) will be modified to simulate short-term (3 consecutive nights) night shift work schedule (kept awake at night and offered sleep opportunities during the day instead) in each of two inpatient stays.
Control (8 hours nocturnal sleep)
Inpatient protocol involves 8-hour sleep opportunity during the biological night throughout.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Simulated short term night shift work schedule
Participant sleep schedules (in the experimental arm) will be modified to simulate short-term (3 consecutive nights) night shift work schedule (kept awake at night and offered sleep opportunities during the day instead) in each of two inpatient stays.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
o Women must be premenopausal, on continuous combination oral contraception and not breastfeeding.
* Willing and able to complete a sleep diary, wear a wrist actigraphy monitor and complete a 3-6 week research study including two 4-night inpatient stays.
* Fully vaccinated against SARS-CoV-2, and willing to produce a negative COVID test result before their first inpatient stay.
Exclusion Criteria
* Night shift work within 1 year prior to study.
* Travel \> 1 time zone within 4 weeks prior to the study or need to travel \>1 time zone during study.
* Physical activity level/regimen incompatible with inpatient CTRC stay.
* Current smokers (or within the previous year of study)
* Positive drug test at screening or inpatient admission
* BMI \> 30 kg/m2
* Individuals who are concurrently participating in another research protocol that would influence their safe participation in this study. For example, participants involved in a study that requires blood draws or ingestion of experimental medication as this would increase the risk of participation in our study and/or compromise study results.
* Any clinically significant unstable medical or surgical condition within the last year (treated or untreated), including history of a clinically significant abnormality of the neurological system (including cognitive disorders or significant head injury) or any history of seizure (including febrile seizure-sleep loss has been used clinically to induce seizures in patients with epilepsy). Given the wide range of illnesses that are encountered in medical practice, it would not be possible to provide a comprehensive list of each and every disease that could serve as grounds for exclusion for the subject. However, the following is a list of illness categories that would certainly be grounds for exclusion: Connective Tissue and Joint Disorders; Neurologic/cognitive Disorders; Musculoskeletal Disorders; Immune Disorders; Chronobiologic Disorders; Cardiovascular Disorders; Respiratory Disorders; Kidney Disorders; Infectious Diseases; Hematopoietic Disorders; Neoplastic Diseases; and Endocrine and Metabolic Diseases.
* Self-reported or newly diagnosed medical condition that is still being investigated or is not under good control, including those identified on screening labs such as:
o Out-of-range values measured on a fasting blood sample: glucose \> 100 mg/dl, thyroid stimulating hormone \<0.5 or \>5.0 uU/ml, abnormal alkaline phosphatase \<39 or \>117 U/l, creatinine, or hemoglobin \<14.5 g/dl men
* Any clinically significant psychiatric condition, as defined by DSM-V. Individuals with a history of most psychiatric illnesses or psychiatric disorders will be excluded, such as but not limited to depression, anxiety, alcoholism, drug dependency, schizophrenic disorders, and personality disorders (performed by medical history and physician interview). However, a personal history of limited prior counseling, psychotherapy (e.g., for adjustment reactions) will NOT be exclusionary.
* Evaluation of Psychiatric/Psychological Suitability:
* Inability to demonstrate a full understanding of the requirements and demands of the study.
* Each participant will complete psychological screening questionnaires. Exclusionary: Center for Epidemiological Studies Depression (CES-D) \> 16. Subject responses to the CES-D are reviewed immediately and appropriate referrals are made if necessary.
* Individuals who are unaware of specific psychiatric diagnoses who have a history of having been treated with antidepressants, neuroleptic medications or major tranquilizers will be excluded from study.
* Use of anti-depressants or any like therapeutics prescribed by a physician is exclusionary
* Individuals with any clinically significant sleep disorder; Diagnosis or symptoms of sleep disorders (history of significant parasomnia as an adult \[night terrors, frequent sleep walking\], insomnia, including but not limited to hypersomnias such as apnea, periodic limb movements, narcolepsy). Sleep disorders will be screened by self-report and physician interview including use of validated sleep questionnaires (PSQI, Epworth sleepiness scale, and Berlin sleep questionnaire for sleep apnea). The following scores will be used to exclude those with sleep disorders: PSQI \>5, Epworth Sleepiness Scale \>9.
* Individuals on medications known to affect bone turnover (e.g., glucocorticoids, osteoporosis medications);
* Use of medications/supplements/drugs that impact sleep or bone metabolism (such as but not limited to sleep medications, marijuana, etc.) within one month (participants can be studied at a later date).
* Dwelling below Denver altitude (1,600 m) 1 month prior to enrollment.
* Greater than moderate caffeine (\>500 mg/day) or alcohol use (\>14 standard drinks/ week or \>5 drinks in one sitting)
* Inability to travel to the CU-AMC campus for study visits.
* Individuals with restrictive diets (e.g., vegan)
* Individuals with 25OHD \< 20 ng/mL (may be studied at a later date)
* Individuals with eGFR \< 60 mL/min/1.73m2 as this is known to affect CTX measurements.
* Z-score \< -2.0 for bone mineral density at the L-spine, femoral neck, or total hip on baseline DXA as compared to the DXA machine's normative database.
* Symptoms of active illness (e.g., fever) at time of enrollment; note - participant may be studied at a later date.
* Restrictive diets that cannot be accommodated by the CTRC Nutrition Core
* Any other reason that participant may not be able to safely complete the entire study, at PI discretion
20 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
University of Colorado, Denver
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christine M Swanson, MD, MCR
Role: PRINCIPAL_INVESTIGATOR
CU Anschutz
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CU Anschutz
Aurora, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20-3013
Identifier Type: -
Identifier Source: org_study_id